Inventiva (NASDAQ:IVA) Given New $13.00 Price Target at HC Wainwright

Inventiva (NASDAQ:IVA) had its price target decreased by equities researchers at HC Wainwright from $14.00 to $13.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 437.19% from the stock’s current price.

Separately, Stifel Nicolaus lowered their price target on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, September 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $16.25.

Inventiva Trading Down 6.9 %

Shares of IVA stock opened at $2.42 on Tuesday. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.75. The stock has a 50 day moving average price of $2.16 and a two-hundred day moving average price of $2.79.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC purchased a new position in Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.